Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 133-144, February 2009

Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression

Department of Physiological Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 6, 55099 Mainz, Germany

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1521-690X(08)00101-2

doi:10.1016/j.beem.2008.09.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 133-144, February 2009

Article Tools